$HRTX News

Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement

HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral

Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...

Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision

Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?

Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)

HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2

Needham Downgrades Heron Therapeutics to Hold

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

U.S. District Court Issues Decision Regarding CINVANTI® Patents

Heron Therapeutics To Appeal Delaware Court Ruling Invalidating Two CINVANTI Patents In Litigation With Azurity

Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?

Heron Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges